- Home
- WGRX vs CTSO Comparison
WGRX vs CTSO Comparison
Compare WGRX & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- CTSO
- Stock Information
- Founded
- WGRX 2022
- CTSO 1997
- Country
- WGRX United States
- CTSO United States
- Employees
- WGRX N/A
- CTSO N/A
- Industry
- WGRX Other Pharmaceuticals
- CTSO Medical/Dental Instruments
- Sector
- WGRX Health Care
- CTSO Health Care
- Exchange
- WGRX Nasdaq
- CTSO Nasdaq
- Market Cap
- WGRX 54.8M
- CTSO 58.6M
- IPO Year
- WGRX 2025
- CTSO N/A
- Fundamental
- Price
- WGRX $0.58
- CTSO $0.92
- Analyst Decision
- WGRX
- CTSO Buy
- Analyst Count
- WGRX 0
- CTSO 2
- Target Price
- WGRX N/A
- CTSO $5.50
- AVG Volume (30 Days)
- WGRX 1.2M
- CTSO 70.7K
- Earning Date
- WGRX 11-11-2025
- CTSO 11-06-2025
- Dividend Yield
- WGRX N/A
- CTSO N/A
- EPS Growth
- WGRX N/A
- CTSO N/A
- EPS
- WGRX N/A
- CTSO N/A
- Revenue
- WGRX $36,738,599.00
- CTSO $36,107,520.00
- Revenue This Year
- WGRX N/A
- CTSO $11.93
- Revenue Next Year
- WGRX N/A
- CTSO $21.22
- P/E Ratio
- WGRX N/A
- CTSO N/A
- Revenue Growth
- WGRX 82384.51
- CTSO 20.18
- 52 Week Low
- WGRX $0.56
- CTSO $0.71
- 52 Week High
- WGRX $7.04
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- WGRX 28.88
- CTSO 45.81
- Support Level
- WGRX $0.57
- CTSO $0.91
- Resistance Level
- WGRX $0.67
- CTSO $0.96
- Average True Range (ATR)
- WGRX 0.10
- CTSO 0.05
- MACD
- WGRX -0.03
- CTSO -0.00
- Stochastic Oscillator
- WGRX 2.56
- CTSO 19.17
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.